CTO
Citius Oncology, Inc. (CTOR) Q1 2026 Earnings
CTOR·Reported May 15, 2026·Before market open
Citius Oncology, Inc. reported Q1 2026 revenue of $1.7M, missed analyst consensus of $7.0M by $5.3M. Diluted EPS came in at $-0.27, missed the $-0.01 consensus by $0.26.
Revenue
$1.7Mmissed by $5.3M
Consensus: $7.0MDiluted EPS
$-0.27missed by $0.26
Consensus: $-0.01
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Citius Oncology, Inc.'s Q1 2026 earnings report.
Citius Oncology, Inc. (CTOR) reported Q1 2026 earnings on May 15, 2026 before market open.
Citius Oncology, Inc. reported revenue of $1.7M and diluted EPS of $-0.27 for Q1 2026.
Revenue missed the consensus estimate of $7.0M by $5.3M. EPS missed the consensus estimate of $-0.01 by $0.26.
You can read the 8-K earnings release (0001213900-26-057883) and the 10-Q periodic report (0001213900-26-057841) directly on SEC EDGAR. The filing index links above go to sec.gov.